India bans use of PET in pharmaceutical industry
The Ministry stated that the use of PET and plastic packaging for pharmaceutical products is hazardous to humans’ health due to the presence of endocrine disruptors. It was also decided that India had different environmental conditions than some of the developed countries which continue to use similar packaging as temperatures in the country reach as high as 45-50 degrees centigrade, creating greater risks of degradation. The pharmacy companies were given six months to switch to glass packaging in spite of the fact that it is much more expensive. Glass packaging provides healthier conditions and preserves the efficacy of liquid formulations, according to government officials.
The value of the PET market in the country was estimated to be around $1.6 billion, and before the ban, it was expected to reach $2.15 billion by 2016, according to industry analysts.
More free plastics newsPlastic resin (PP, LDPE, LLDPE ,HDPE, PVC, GPS; HIPS, PET, ABS) prices, polymer market trends, and more...
- 3-digit hikes in Oct PVC offers reinforce supply-driven bullishness in Asia
- Crude oil caught between demand woes and production disruption
- Tightness drives European PVC market up, prices near pre-pandemic levels
- Major LDPE markets touch multi-year highs on growing tightness
- A prospect for Q4 through uncharted waters of 2020 amid pandemic
- China's import PP markets maintain uptrend under shadow of oil-driven losses in Dalian futures
- Weaker domestic demand prompts Vietnam to export polymers
- European PP market ceases upward trend in September
- Force majeure declarations rock the boat in Turkish PVC market
- China’s PE uptrend fueled by US force majeures; LDPE soars to more than 1-year high